Evaluation of antiviral activity and toxicity of reconbinant human interferon alfa-2a in calves persistently infected with type 1 bovine viral diarrhea virus

American Journal of Veterinary Research

Volumn 65, Issue 6, 2004, Pages 865-870

  Peek, Simon F ^a   Bonds, Michael D ^a   Schaele, Patrick ^a   Weber, Sarah ^a   Friedrichs, Kristin ^a   Schultz, Ronald D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON ANTIBODY; RECOMBINANT ALPHA2A INTERFERON;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; BOVINE DIARRHEA VIRUS; CATTLE DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VIVO STUDY; MICROCYTIC ANEMIA; NONHUMAN; PERSISTENT INFECTION; PHYSICAL EXAMINATION; VIRUS LOAD;

ANIMALS; ANTIBODIES; ANTIVIRAL AGENTS; BLOOD CHEMICAL ANALYSIS; BOVINE VIRUS DIARRHEA-MUCOSAL DISEASE; CATTLE; CATTLE DISEASES; DIARRHEA VIRUS 1, BOVINE VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON ALFA-2A; VIRAL LOAD;

ANIMALIA; BOS TAURUS; BOVINAE; BOVINE VIRAL DIARRHEA VIRUS 1;

EID: 3042678857     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.865     Document Type: Article

References (23)

1. Baker JC. The clinical manifestations of bovine viral diarrhea infection. Vet Clin North Am Food Anim Pract 1995;11:425-445.
2. Balfour HH Jr. Antiviral drugs. N Engl J Med 1999; 340:1255-1268.
3. Chemello L, Cavalletto L, Noventa F, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. J Viral Hepat 1995;2:91-96.
4. Charleston B, Fray MD, Baigent S, et al. Establishment of persistent infection with non-cytopathic bovine viral diarrhoea virus in cattle is associated with a failure to induce type I interferon. J Gen Virol 2001;82:1893-1897.
5. Schweizer M, Peterhans E. Non-cytopathic bovine viral diarrhea virus inhibits double-stranded RNA-induced apoptosis and interferon synthesis. J Virol 2001;75:4692-4698.
6. Peek SF, Bonds MD, Gangemi DG, et al. Evaluation of cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against bovine viral diarrhea virus, infectious bovine rhinotracheitis virus, and vesicular stomatitis virus in vitro. Am J Vet Res 2004;65:865-868.
7. Saliki JT, Fulton RW, Hull SR, et al. Microtiter virus isolation and enzyme immunoassays for detection of bovine viral diarrhea virus in cattle serum. J Clin Microbiol 1997;35:803-807.
8. Dubovi EJ. The diagnosis of bovine viral diarrhea infections - a laboratory review. Vet Med 1990;85:1133-1139.
9. Corapi NW, Donis RO, Dubovi EJ. Characterization of a panel of monoclonal antibodies and their use in the study of the antigenic diversity of bovine viral diarrhea virus. Am J Vet Res 1990;51:1388-1394.
10. Bolin SR, Littledike ET, Ridpath JF. Serologic detection and practical consequences of antigenic diversity among bovine viral diarrhea viruses in a vaccinated herd. Am J Vet Res 1991;52:1033-1037.
11. Sentsui H, Takami R, Nishimore T, et al. Anti-viral effect of interferon-α on bovine viral diarrhea virus. J Vet Med Sci 1998; 60:1329-1333.
12. Horsiberger MA, De Staritzky K. A recombinant human interferon-α B/D hybrid with a broad host range. J Gen Virol 1987; 68:945-948.
13. Cutrone EC, Langer JA. Identification of critical residues in bovine IFNAR-1 responsible for interferon binding. J Biol Chem 2001; 276:17140-17148.
14. Bridgman R, Rossi CR, Campos M. The sensitivity of domestic animal cell lines to 8 recombinant human interferons. J Interferon Res 1988;8:173-175.
15. Gresser I, Bandu MT, Brouty-Boye D. Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature 1974; 251:543-545.
16. Kubes M, Fuchsberger N, Kontsek P. Cross species antiviral and antiproliferative activity of human interferon omega. J Interferon Res 1994;14:57-59.
17. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 2003;59:1-11.
18. Saito T, Ito T, Ishiko H, et al. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. Am J Gastroenterol 2003;98:1377-1383.
19. Saracco G, Rizzetto M. A practical guide to the use of interferons in the management of hepatitis virus infections. Drugs 1997; 53:74-85.
20. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
21. Castera L, Zigante F, Bastie F, et al. Incidence of interferon alpha induced depression in patients with chronic hepatitis C. Hepatology 2002;35:978-979.
22. Saracco G, Rizzetto M. The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review. Gastroenterol Hepatol 1995;10:668-673.
23. Giannelli AG, Currenti M, Simeoni E, et al. Antibodies to interferon in hepatitis C patients relapsing while continuing recombinant IFN-alpha 2 therapy. Clin Exp Immunol 1996; 104:384-387.